Patent · US Expired

Antibodies against the interferon (IFN) .alpha./.beta. receptor (IFNAR2) that preferentially block the activity of IFN-.alpha.

US6136309A · kind A · utility

26Cited by

0References

24Claims

0Family size

Assignee

YEDA RESEARCH AND DEVELOPMENT CO. LTD. · IL

Inventors

Daniela Novick · Rehovot, IL
Menachem Rubinstein · Nes Ziona, IL

Key dates

Filing date	Oct 29, 1998
Grant date	Oct 24, 2000
Priority date	—
Expiry date	Oct 29, 2018

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies directed against the ligand-binding component of the interferon (IFN)-.alpha./.beta. receptor (IFN.alpha./.beta.R, IFNAR2) are provided. The antibodies are capable of selectively modulating the activity of IFN-.alpha. as compared to IFN-.beta.. By virtue of their selectivity, the antibodies are useful in clinical and analytical applications.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.